Veru (VERU) Total Operating Expense: $27.70 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VERU Veru Inc VERU
27 GF Score
Price $2.51
! 3 Warning Signs
View Full Analysis

What is Veru Total Operating Expense?

Veru VERU +2.87% 27 Total Operating Expense is $27.70 Mil as of Jun. 2026. GuruFocus rates VERU with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

Veru's Total Operating Expense for the three months ended in Jun. 2026 was $7.69 Mil. Veru's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was $27.70 Mil.

Veru Total Operating Expense Related Terms

Veru Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Veru's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veru Total Operating Expense Chart

Veru Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.25 114.01 103.10 37.12 35.38

Veru Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 7.43 5.40 7.19 7.69
VERU
27GF Score
Veru Inc VERU
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veru Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $27.70 Mil mean?
Veru (VERU) has a Total Operating Expense of $27.70 Mil as of Jun. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Veru and its competitors.
Is Veru's Total Operating Expense too high?
Veru's current Total Operating Expense is $27.70 Mil. Overall, Veru has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Veru's Total Operating Expense compare to TVGN and GRCE?
Veru's Total Operating Expense of $27.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Veru and its competitors. Veru's current Total Operating Expense is $27.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veru stock overvalued right now?
Veru (VERU) has a current Total Operating Expense of $27.70 Mil. The current Total Operating Expense is $27.70 Mil. Veru's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Veru (VERU), the current Total Operating Expense is $27.70 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veru Business Description

Address 2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc. is a biopharmaceutical company based in Miami, Florida, focused on developing medicines for cardiometabolic and inflammatory diseases. Its development pipeline centers on two oral new chemical entities: enobosarm, a selective androgen receptor modulator being studied to preserve lean muscle mass during weight reduction with GLP-1 receptor agonist drugs, and sabizabulin, a microtubule disruptor being developed to reduce inflammation in atherosclerotic cardiovascular disease. The company also markets a sexual health consumer product, the FC2 Female Condom, through its commercial business, which generates revenue and helps fund research. Veru's earlier work included drug candidates for breast and prostate cancer and for viral and inflammatory conditions. Its customers include patients, healthcare providers, and public health organizations, with the FC2 product sold in the United States and internationally, including through government and institutional buyers.
27GF Score

Get the complete analysis for VERU

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.51
Price